Home / Human Healthcare / Human Probiotic / Lobun

Chronic kidney disease may progress to end-stage renal disease, which requires dialysis or kidney transplantation. No generally applicable therapies to slow progression of renal disease are available. Bacteriotherapy affords a promising approach to mitigate uremic intoxication by ingestion of live microbes able to catabolize uremic solutes in the gut. Azotemia, the accumulation of nitrogenous waste products, chiefly urea, in the blood, is the hallmark of renal failure. Urea is the predominant nitrogen waste product of protein catabolism.

According to the World Health Organization, kidney disease and disease of the urinary tract cause 850,000 deaths worldwide every year. Globally, CKD is the 12th leading cause of death and the 17th leading cause of disability. People with CKD are at high risk for heart disease and stroke and they are more likely to die of a heart attack or stroke than of CKD. Moreover, patients with Diabetes and Cardiovascular disease are at high risk of CKD. Even though kidney disease has been graded, detecting the disease is still a major problem. Despite the best of the preventive treatment for ESRD [end-stage-renal-disease] the patient has to undergo dialysis at periodic intervals, ultimately leading to a transplant.

In order to delay the progression of the disease, the nephrologist imposes dietary regulations, regulated water intake etc. An effective treatment strategy or plan is yet to be developed to prevent the progression of CKD to ESRD. However bio-therapeutics using beneficial microbes have been studied, and are now a part of the nephrologists therapeutic regimen to reduce the putrefactive bacterial load in the GI tract, that increase the toxin load which consists of BUN, ammonia and other by-products of protein metabolism, which further worsen the prognosis and survival of the patients.

Combi-probiotics, with a pre-biotic containing FOS [fructo-oligosaccharide] are being used as an enetric-dialyzer for removal of proteinaceous, by-products. Many of the entero-toxins are removed by dialysis, however a rebound phenomenon has been observed, with a rapid rise in enterotoxins and BUN. Studies have shown, that probiotics effectively control and reduce the eneterotoxins to a great extent, thereby limiting the progression of the disease.

Probiotics containing, beneficial microbes, are now being used in patients diagnosed with CKD to delay the progression and limit the damage to the kidney from entetoxins. Preventing uremic syndrome, is the biggest challenge and a study using Sanzyme's prebiotic and probiotic combination of LOBUN Capsuless has shown promising results, while delaying the progression of CKD and improving the QOL [Quality of Life] over a 12 month study.

  Copyright © 2014 Sanzyme. All rights reserved.